Latest market price
36.04
+0.15+0.42%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -0.44 | Insider Own | 21.92% | Shs Outstand | 722.32M | Perf Week | -1.37% |
| Market Cap | 25.92B | Forward P/E | — | EPS next Y | -1.30 | Insider Trans | -5.05% | Shs Float | 582.20M | Perf Month | 0.73% |
| Enterprise Value | 22.18B | PEG | — | EPS next Q | -0.37 | Short Float | 6.92% | Perf Quarter | 4.16% | ||
| Income | -267.00M | P/S | — | EPS this Y | — | Short Ratio | 5.64 | Perf Half Y | 27.26% | ||
| Sales | 8.00M | P/B | 5.27 | EPS next Y | — | ROA | -5.02% | Short Interest | 40.30M | Perf YTD | 66.08% |
| Book/sh | 6.81 | P/C | 6.75 | EPS next 5Y | — | ROE | -6.12% | 52W High | 42.50 -15.20% | Perf Year | 80.29% |
| Cash/sh | 5.32 | P/FCF | — | EPS past 3/5Y | — | ROIC | -27.14% | 52W Low | 19.30 86.74% | Perf 3Y | 330.07% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | -37.00% -19.73% | Gross Margin | 81.21% | Volatility | 3.01% 3.52% | Perf 5Y | 328.54% |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | -18140.92% | ATR (14) | 1.32 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 16.72 | Sales Y/Y TTM | -65.22% | Profit Margin | -3534.88% | RSI (14) | 49.51 | Recom | 2.13 |
| Dividend Gr. 3/5Y | — | Current Ratio | 16.72 | EPS Q/Q | -31.08% | SMA20 | 1.53% | Beta | 1.18 | Target Price | 47.71 |
| Payout | 0.00% | Debt/Eq | 0.02 | Sales Q/Q | -50.00% | SMA50 | -1.61% | Rel Volume | 0.87 | Prev Close | 35.89 |
| Employees | 721 | LT Debt/Eq | 0.02 | Earnings | Nov 09 | SMA200 | 13.94% | Avg Volume | 7.67M | Price | 36.04 |
| IPO Date | Dec 08, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -10.14% -29.89% | Net Debt/EBITDA | — | Volume | 6,683,336 | Change | 0.42% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-12-26 | Downgrade | Wolfe Research | Outperform → Peer Perform | |
| Sep-16-26 | Initiated | Stifel | Buy | $51 |
| Sep-09-26 | Reiterated | UBS | $55 | |
| Sep-09-26 | Reiterated | Guggenheim | Buy | $36 → $46 |
| Sep-08-26 | Reiterated | Jefferies | Buy | $30 → $52 |
| Sep-08-26 | Reiterated | HC Wainwright & Co. | Buy | $41 → $47 |
| Aug-07-26 | Reiterated | HC Wainwright & Co. | Buy | $34 → $41 |
| May-26-26 | Reiterated | Guggenheim | Buy | $30 → $36 |
| May-21-26 | Reiterated | Cowen & Co. | Outperform | $38 → $41 |
| May-21-26 | Reiterated | Leerink Partners | Outperform | $32 → $42 |
Latest News· Times ET
Oct-29-26
Oct-29-2609:00AM
Oct-24-26
Oct-24-2603:16PM
Oct-21-26
Oct-21-2603:04PM
11:04AM
07:00AM
07:00AM
Oct-18-26
Oct-16-26
Oct-16-2603:47AM
Oct-12-26
Oct-12-2605:03AM
Oct-06-26
Oct-06-2606:15AM
Oct-04-26
Oct-04-2609:02AM
Oct-01-26
Oct-01-2603:15PM
Sep-28-26
Sep-28-2604:02AM
Sep-24-26
Sep-24-2601:02PM
Sep-23-26
Sep-23-2607:00AM
Company
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 3/31/2026 | FY 2024 3/31/2025 | FY 2023 3/31/2024 | FY 2022 3/31/2023 | FY 2021 3/31/2022 | FY 2020 3/31/2021 | FY 2019 3/31/2020 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 8 | 8 | 29 | 33 | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1 | 1 | 1 | 2 | — | — | — | — | |
| Gross Profit | 5 | 7 | 28 | 31 | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 642 | 610 | 591 | 416 | — | — | — | — | |
| Research and Development | 731 | 682 | 550 | 440 | — | — | — | — | |
| Other Operating Expense | -1 | 0 | 1 | 0 | — | — | — | — | |
| Operating Income | -1,366 | -1,285 | -1,114 | -825 | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 35 | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 1,076 | 1,021 | 432 | 5,428 | — | — | — | — | |
| Net Income Before Taxes | -290 | -265 | -682 | 4,568 | — | — | — | — | |
| Income Taxes | 124 | 133 | 48 | 22 | — | — | — | — | |
| Consolidated Net Income | -267 | -300 | -172 | 4,349 | — | — | — | — | |
| Net Income From Continuing Operations | -415 | -398 | -730 | 4,546 | — | — | — | — | |
| Net Income | -267 | -300 | -172 | 4,349 | — | — | — | — | |
| EPS (Recurring) | -0.38 | -0.43 | -0.24 | 5.55 | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.38 | -0.43 | -0.24 | 5.55 | — | — | — | — | |
| EPS (Diluted) | -0.44 | -0.43 | -0.24 | 5.23 | — | — | — | — | |
| EBITDA | -287 | -261 | -668 | 4,625 | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | 2.02 | — | — | — | — | |
| Price To Sales Ratio | 3,248.11 | 2,402.98 | 252.25 | 250.09 | — | — | — | — | |
| Gross Margin | 62.50 | 87.50 | 96.55 | 93.94 | — | — | — | — | |
| Operating Margin | -17,075.00 | -16,062.50 | -3,841.38 | -2,500.00 | — | — | — | — | |
| Net Margin | -3,337.50 | -3,750.00 | -593.10 | 13,178.79 | — | — | — | — | |
| Shares Outstanding | 721 | 694 | 725 | 783 | — | — | — | — | |
| Market Capitalization | 25,985 | 19,224 | 7,315 | 8,253 | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Venker Eric | President & Immunovant CEO | Oct 28 '26 | Sale | 36.59 | 200,000 | 7,318,000 | 1,199,154 | Oct 30 |
| Venker Eric | President & Immunovant CEO | Oct 20 '26 | Sale | 35.11 | 200,000 | 7,022,667 | 1,399,154 | Oct 22 |
| Epperly Melissa B, | Director | Oct 01 '26 | Sale | 36.10 | 17,750 | 640,861 | 14,954 | Oct 05 |
| Epperly Melissa B, | Director | Oct 01 '26 | Option Exercise | 4.46 | 17,750 | 79,165 | 32,704 | Oct 05 |
| Venker Eric | President & Immunovant CEO | Sep 30 '26 | Option Exercise | 3.85 | 200,000 | 770,000 | 1,799,154 | Oct 02 |
| Venker Eric | President & Immunovant CEO | Sep 30 '26 | Sale | 36.62 | 200,000 | 7,324,000 | 1,599,154 | Oct 02 |
| Epperly Melissa B, | Director | Sep 15 '26 | Sale | 39.74 | 4,938 | 196,230 | 9,900 | Sep 17 |
| Fitzgerald Meghan | Director | Sep 15 '26 | Sale | 39.74 | 5,112 | 203,152 | 36,108 | Sep 17 |
| Fitzgerald Meghan | Director | Sep 08 '26 | Option Exercise | 8.80 | 20,000 | 176,000 | 62,963 | Sep 10 |
| Fitzgerald Meghan | Director | Sep 08 '26 | Sale | 39.90 | 20,000 | 798,000 | 42,963 | Sep 10 |
| Venker Eric | President & Immunovant CEO | Aug 28 '26 | Option Exercise | 3.85 | 200,000 | 770,000 | 1,799,154 | Sep 01 |
| Venker Eric | President & Immunovant CEO | Aug 28 '26 | Sale | 35.77 | 200,000 | 7,153,393 | 1,599,154 | Sep 01 |
| Sukhatme Mayukh | President & CIO | Aug 21 '26 | Sale | 36.48 | 144,756 | 5,280,699 | 18,630,739 | Aug 21 |
| Sukhatme Mayukh | President & CIO | Aug 21 '26 | Option Exercise | 3.85 | 144,756 | 557,311 | 18,775,495 | Aug 21 |
| Sukhatme Mayukh | President & CIO | Aug 20 '26 | Option Exercise | 3.85 | 17,519 | 67,448 | 18,648,258 | Aug 21 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.